We are live on
!
Find out more
CAC
Cowen and Company Portfolio holdings
AUM
$2.97B
1-Year Est. Return
105.26%
This Fund
S&P 500
This Quarter
Est. Return
+18.1%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.06%
5 Year Est. Return
+670.57%
10 Year Est. Return
–
AUM
$1.52B
AUM Growth
+$95.3M
(+6.7%)
Cap. Flow
-$53M
Cap. Flow
% of AUM
-3.48%
Top 10 Holdings %
Top 10 Hldgs %
46.4%
Holding
811
New
169
Increased
201
Reduced
172
Closed
223
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTC Therapeutics
PTCT
|
+$66.9M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$26.6M |
| 3 |
Imperial Oil
IMO
|
+$24.9M |
| 4 |
Coinbase
COIN
|
+$22.5M |
| 5 |
ANSCU
Agriculture & Natural Solutions Acquisition Corp Unit
ANSCU
|
+$21.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdvisorShares Pure US Cannabis ETF
MSOS
|
+$48.7M |
| 2 |
AAC
Ares Acquisition Corporation
AAC
|
+$36.4M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$27.6M |
| 4 |
HCVIU
Hennessy Capital Investment Corp. VI Unit
HCVIU
|
+$17.4M |
| 5 |
NETD
Nabors Energy Transition Corp II
NETD
|
+$16.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.8% |
| 2 | Financials | 24.55% |
| 3 | Technology | 21.73% |
| 4 | Communication Services | 4.41% |
| 5 | Energy | 3.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NVIDIA
NVDA
$4.72T
| $270M | 17.74% |
5,461,890
-245,320
| -4% | -$11.4M |
|
|
2
PTC Therapeutics
PTCT
$6.26B
| $103M | 6.73% |
3,725,626
+2,926,115
| +366% | +$66.9M |
|
|
3
Coinbase
COIN
$43.1B
| $64.6M | 4.24% |
371,471
+206,395
| +125% | +$22.5M |
|
|
RNAM
4
DELISTED
Avidity Biosciences
RNAM
| $50.9M | 3.34% |
5,629,103
| – | – |
|
5
SiriusXM
SIRI
$10.4B
| $39.3M | 2.57% |
717,661
+80,061
| +13% | +$3.85M |
|
6
Tarsus Pharmaceuticals
TARS
$2.6B
| $38.7M | 2.54% |
1,911,399
+114,626
| +6% | +$1.91M |
|
|
CVII
7
DELISTED
Churchill Capital Corp VII Class A Common Stock
CVII
| $38.1M | 2.5% |
3,630,222
+829,757
| +30% | +$8.7M |
|
8
Immunocore
IMCR
$1.72B
| $36.7M | 2.4% |
536,487
+76,451
| +17% | +$3.97M |
|
9
State Street Energy Select Sector SPDR ETF
XLE
$39.2B
| $33M | 2.16% |
787,204
-324,400
| -29% | -$13.9M |
|
10
Rocket Pharmaceuticals
RCKT
$351M
| $33M | 2.16% |
1,100,000
| – | – |
|
11
Mercer International
MERC
$39.5M
| $31.3M | 2.05% |
3,300,000
| – | – |
|
|
SCRM
12
DELISTED
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
| $30.4M | 2% |
2,870,029
+1,652,818
| +136% | +$17.4M |
|
|
SAGE
13
DELISTED
Sage Therapeutics
SAGE
| $29M | 1.9% |
+1,339,971
| New | +$26.6M |
|
14
Alibaba
BABA
$279B
| $24.7M | 1.62% |
319,151
+191,255
| +150% | +$15.2M |
|
|
15
Imperial Oil
IMO
$62.3B
| $24.7M | 1.62% |
+433,016
| New | +$24.9M |
|
16
Energy Transfer Partners
ET
$69.6B
| $24.5M | 1.61% |
1,777,000
+472,000
| +36% | +$6.41M |
|
17
Establishment Labs
ESTA
$2.75B
| $24.3M | 1.6% |
939,948
-201,224
| -18% | -$5.89M |
|
18
Fulcrum Therapeutics
FULC
$248M
| $23.4M | 1.54% |
3,473,934
-834,425
| -19% | -$3.7M |
|
|
AVDL
19
DELISTED
Avadel Pharmaceuticals
AVDL
| $23.2M | 1.52% |
1,642,347
-695,955
| -30% | -$8.18M |
|
|
ANSCU
20
Agriculture & Natural Solutions Acquisition Corp Unit
ANSCU
| $21.7M | 1.42% |
+2,135,000
| New | +$21.6M |
|
21
ARK Innovation ETF
ARKK
$5.77B
| $20.2M | 1.32% |
+384,920
| New | +$16.7M |
|
22
Stoke Therapeutics
STOK
$1.87B
| $19.6M | 1.28% |
3,721,659
| – | – |
|
23
Meta Platforms (Facebook)
META
$1.37T
| $14M | 0.92% |
39,465
-35,988
| -48% | -$11.7M |
|
|
RRAC
24
DELISTED
Rigel Resource Acquisition Corp.
RRAC
| $12.9M | 0.85% |
1,176,493
-554,990
| -32% | -$6.07M |
|
|
LCAA
25
DELISTED
L Catterton Asia Acquisition Corp Class A Ordinary Shares
LCAA
| $11.3M | 0.74% |
1,049,264
-235,025
| -18% | -$2.52M |
|
Similar funds
CIP
PWLP
FPCG
SI
BC
FTDI
CIM
PRO
Cowen and Company's Q4 2023 Portfolio in Review
As of Q4 2023, Cowen and Company held 811 positions worth $1.52B, up 6.7% from $1.43B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Cowen and Company withdrew a net $53M in Q4 2023, closing 223 positions and reducing 172 holdings. Its most notable exit was AdvisorShares Pure US Cannabis ETF, an estimated $48.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 22% a quarter earlier, followed by Financials and Technology.
Against the trend, Cowen and Company opened a new position in Sage Therapeutics worth $29M.
- Cowen and Company's largest Q4 2023 buy was Sage Therapeutics: 1,339,971 shares worth $29M.
- Cowen and Company added most to PTC Therapeutics in Q4 2023, an estimated $66.9M increase.
- Cowen and Company's biggest Q4 2023 reduction was Nabors Energy Transition Corp II, cutting an estimated $16.9M.
- Cowen and Company fully exited AdvisorShares Pure US Cannabis ETF in Q4 2023, selling an estimated $48.7M.
- Cowen and Company's ten largest holdings make up 46% of its $1.52B portfolio in Q4 2023.
- Cowen and Company opened 169 new positions and closed 223 in Q4 2023.
- Cowen and Company's portfolio value rose 6.7% quarter-over-quarter to $1.52B.
Based on Cowen and Company's 13F filing for Q4 2023, filed 8 Feb 2024.